Profile image
Story Views

Last Hour:
Last 24 Hours:

Generic Drugs and Strategies for Commercial Success SWOT Analysis and Development Overview

Friday, January 6, 2017 7:18
% of readers think this story is Fact. Add your two cents.

(Before It's News)

The generic drugs market has seen rapid expansion for more than 30 years, and consistently achieves higher annual growth rates than the overall pharmaceutical market. The increase in generic drug activity can be primarily attributed to the promise of significant revenues from blockbuster drugs nearing patent expiry. In the US – the largest generic drugs market by revenue – the number of generic drug approvals hit a record high in 2015, due to a new program that aimed to speed up approvals. There has also recently been a surge in the number of industry-transforming mergers and acquisitions, with companies looking to consolidate their position in this highly lucrative market.

The results of GBI’s latest industry survey provide insightful analyses from different expert panels, including R&D and commercial, and highlight trends observed in key geographical markets. The survey examined key commercial issues and recent developments in the generic drugs market, such as the reasons behind the surge in mergers and acquisitions, and the likely effects on market dynamics. It covered important factors currently driving or restraining the market, prospects for key therapy areas expected to exhibit significant levels of genericization in the coming years, and the most promising emerging markets for generic companies in terms of revenue potential. Additionally, the survey examined common business strategies and regulations being leveraged by global generic drug companies for market expansion.

For more information about this report at


What is the current value of the generic drugs market, and how will market dynamics change in the coming years?

Will the US continue to dominate the market?

Which therapy areas will witness the highest level of genericization in the next five years?

Request a sample copy at

Reasons to buy

This report will allow you to -

Gain insightful analyses and understanding of market dynamics: This report comprehensively describes and assesses the most important factors driving and restraining the generic drugs market. It assesses pertinent commercial and regulatory aspects of the industry by combining survey results with proprietary in-house expertise and extensive secondary research efforts.

Assess the generic drugs pipeline for top small molecule drugs in the market: Our study provides prospects for these drugs beyond their patent expiries, including potential generic competition, expected launch dates and revenue forecasts to 2021.

Evaluate the strategies used by companies to promote generic drug usage: This report provides insights regarding the various commercial strategies being adopted and leveraged by generic drug companies to promote their therapies.

Understand government policies and strategies to promote generic drug usage: This report assesses current strategies and regulations implemented by governments in key geographic markets to promote generic drug usage.

Gain insight on mergers and acquisitions in the global generic drugs market: This report describes industry-transforming mergers and acquisitions that have occurred in recent years, the reasons behind the recent surge in these types of transactions, and their likely impact on market dynamics.

Tables of Content:

Table 1: Generic Drugs by Type 9

Table 2: Generic Drug Entry Strategies 11

Table 3: Branded Drugs for which Authorized Generics Were Launched in US in 2015 38

Table 4: Selection of Branded Drugs for which First-Time Generics Have Been Launched in the US in 2015 39

Table 5: Super Generics Approved in the US, 2010–2014 40

Table 6: Super Generics Under Development in the US, 2016 41

Table 7: Teva, SWOT Analysis 58

Table 8: Sandoz, SWOT Analysis 59

Table 9: Mylan, SWOT Analysis 60

Table 10: Sun Pharma, SWOT Analysis 61

Table 11: Aspen, SWOT Analysis 62

Table 12: Hospira, SWOT Analysis 63

Table 13: Fresenius Kabi, SWOT Analysis 64

Table 14: Lupin, SWOT Analysis 65

Ask for Discount at

Contact Us:                 
Call: +1-646-491-9876

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.